Business
Statement re Share Price Movement
Statement re Share Price Movement.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n\n\n\n\n (AIM: SAR) 9 February 2011\n\n\n SAREUM HOLDINGS PLC\n (\"Sareum\" or the \"Company\")\n\n Statement re Share Price Movement\n\nSareum (AIM: SAR), the specialist cancer drug discovery business, has noted the\nrecent significant rise in the Company's share price, the volume of shares\ntraded in the last two trading sessions and the bulletin board and press\ncomments following the announcement made on 7 February 2011 with the headline\n\"Research Update: Positive Leukaemia Model Study\".\nThe Company can confirm that it is not currently in advanced stages of\ndiscussion with a potential licencing partner and there can be no certainty that\nthe announcement of these results will lead to a licencing agreement being\nentered into.\n\nThe Company can confirm that the results of the study have, in the ordinary\ncourse of business, been sent to potential licencing partners and the Company\nwill be engaging with these partners to determine their interest in the data.\n\n Sareum Holdings plc\n\n Tim Mitchell 01223 497 700\n\n\n\n Merchant Securities Limited (Nomad)\n\n Simon Clements/Bidhi Bhoma 020 7628 2200\n\n\n\n Hybridan LLP (Broker)\n\n Claire Noyce 020 7947 4350\n\n\nNotes for editors:\n\nAbout Sareum Holdings plc\nSareum is a drug discovery company, headquartered in Cambridge UK, that is\nfocused on producing targeted small molecule therapeutics to address unmet\nmedical needs, primarily in cancer. Sareum aims to successfully deliver drug\ncandidates for licensing to pharmaceutical and biotechnology companies at the\npre-clinical or early clinical trials stage.\n\nSareum's Chk1 kinase cancer research programme is a joint research collaboration\nwith The Institute of Cancer Research and Cancer Research Technology Limited.\nNovel chemical compounds developed by the collaboration have been shown to\nincrease the effectiveness of current cancer therapeutics in in-vivo cancer\nmodels.\n\nSKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology\nplatform that has so far produced the Company's Aurora+FLT3, Aurora+ALK VEGFR-\n3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL\ncan also generate drug research programmes against other kinase targets.\n\nSareum Holdings plc joined the AIM market of the London Stock Exchange in\nOctober 2004, trading under the symbol SAR.Â&nb...